Squarepoint’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$421K Sell
31,955
-10,529
-25% -$235K ﹤0.01% 3554
2026
Q1
$1.12M Buy
42,484
+39,714
+1,434% +$4.99M ﹤0.01% 2682
2025
Q4
$687K Buy
+2,770
New +$632K ﹤0.01% 2935
2025
Q2
– Sell
-2,724
Closed -$240K – 4694
2025
Q1
$240K Buy
2,724
+1,825
+203% +$169K ﹤0.01% 3899
2024
Q4
$65.1K Sell
899
-938
-51% -$64.3K ﹤0.01% 4798
2024
Q3
$145K Buy
+1,837
New +$141K ﹤0.01% 3788
2024
Q2
– Sell
-3,750
Closed -$354K – 4283
2024
Q1
$354K Buy
3,750
+3,169
+545% +$279K ﹤0.01% 3280
2023
Q4
$42.4K Buy
+581
New +$34.3K ﹤0.01% 3865
2023
Q3
– Sell
-1,876
Closed -$180K – 3965
2023
Q2
$180K Sell
1,876
-6,373
-77% -$635K ﹤0.01% 3255
2023
Q1
$832K Sell
8,249
-3,188
-28% -$488K ﹤0.01% 2005
2022
Q4
$1.99M Buy
11,437
+8,430
+280% +$5.55M 0.01% 1368
2022
Q3
$2.88M Buy
3,007
+2,600
+639% +$2.58M 0.01% 1074
2022
Q2
$273K Sell
407
-227
-36% -$141K ﹤0.01% 2328
2022
Q1
$440K Buy
+634
New +$489K ﹤0.01% 2078
2021
Q3
– Sell
-132
Closed -$86K – 3106
2021
Q2
$86K Sell
132
-245
-65% -$170K ﹤0.01% 3042
2021
Q1
$279K Sell
377
-299
-44% -$241K ﹤0.01% 2461
2020
Q4
$523K Buy
676
+497
+278% +$392K ﹤0.01% 1786
2020
Q3
$177K Buy
179
+5
+3% +$5.3K ﹤0.01% 2139
2020
Q2
$181K Sell
174
-55
-24% -$55.3K ﹤0.01% 1847
2020
Q1
$186K Sell
229
-189
-45% -$197K ﹤0.01% 1496
2019
Q4
$523K Buy
+418
New +$674K ﹤0.01% 1753

Other funds holding GOSS

Squarepoint's GOSS Position: Q2 2026 in Review

Squarepoint reduced its Gossamer Bio (GOSS) stake by 25% in Q2 2026, selling an estimated $235K and leaving 31,955 shares worth $421K. The position accounts for ﹤0.01% of the portfolio, ranked #3554.

Squarepoint first reported a position in GOSS in Q4 2019 and has held it in 21 quarters since. The position peaked at $2.88M in Q3 2022. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Squarepoint held 31,955 shares of Gossamer Bio worth $421K as of Q2 2026.
  • Squarepoint sold 10,529 Gossamer Bio shares in Q2 2026, an estimated $235K.
  • Gossamer Bio made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3554 holding.
  • Squarepoint first reported a position in Gossamer Bio in Q4 2019 and has held it in 21 quarters since.
  • Squarepoint's Gossamer Bio position peaked at $2.88M in Q3 2022.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.